Sign In
Buy STIM
$1.20
-0.0300 (-2.44%)
At Close: Jun 22, 2026
Neuronetics Appoints Robert Greene as Senior Vice President Sales
04:30pm, Tuesday, 02'nd Jun 2026
MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life
Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026
08:32am, Tuesday, 02'nd Jun 2026
MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life
Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment
08:32am, Thursday, 14'th May 2026
MALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life
Neuronetics, Inc. (STIM) Q1 2026 Earnings Call Transcript
12:41pm, Tuesday, 05'th May 2026
Neuronetics, Inc. (STIM) Q1 2026 Earnings Call Transcript
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
10:15am, Tuesday, 05'th May 2026
Neuronetics (STIM) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.21 per share a year ago.
Neuronetics Reports First Quarter 2026 Financial and Operating Results
07:50am, Tuesday, 05'th May 2026
MALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a vertically integrated, commercial stage, medical technology and healthcare c
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 29'th Apr 2026
MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve t
Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call
08:30am, Tuesday, 21'st Apr 2026
MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improv
Policy Update Broadens Access to Innovative, Non-Drug Depression Treatment Across 26 States and Washington, D.C. Policy Update Broadens Access to Innovative, Non-Drug Depression Treatment Across 26 St
Neuronetics Announces Chief Financial Officer Transition
04:30pm, Monday, 06'th Apr 2026
MALVERN, Pa. , April 06, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve t
Delivers Letter to STIM Board Outlining Potential 5-7x Upside for Shareholders Inherent in Sale of TMS and Standalone Clinic Business BLOOMFIELD HILLS, Mich., April 6, 2026 /PRNewswire/ -- Jorey Chern
Jorey Chernett Acquires 450,000 Shares of Neuronetics (NASDAQ:STIM) Stock
05:20am, Sunday, 22'nd Mar 2026
Neuronetics, Inc. (NASDAQ: STIM - Get Free Report) major shareholder Jorey Chernett acquired 450,000 shares of the company's stock in a transaction that occurred on Thursday, March 19th. The stock was
Neuronetics, Inc. (STIM) Q4 2025 Earnings Call Transcript
01:12pm, Tuesday, 17'th Mar 2026
Neuronetics, Inc. (STIM) Q4 2025 Earnings Call Transcript
Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
07:50am, Tuesday, 17'th Mar 2026
Total revenue of $41.8 million in Q4 2025, up 86% as reported and 23% on an adjusted pro forma basis versus Q4 2024 Greenbrook clinic revenue of $23.5 million in Q4 2025, up 428% as reported and 37% o
Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer
07:45am, Tuesday, 17'th Mar 2026
Seasoned leader brings more than 30 years of medical device experience, with a proven track record of growing revenue, earnings, and cash flow across multiple publicly traded healthcare companies Seas
